Folic acid supplementation and homocyst(e)ine level in renal transplant recipients

Grandtnerova, B.; Laca, Ľ; Gábor, D; Gregová, E.; Korónyi, S

doi:10.1016/s0041-1345(00)02785-8

Cited by 4 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, 50% of group 1 subjects normalized their tHcy levels, while only 9% of group 2 and 0% of group 3 subjects did. Another recent trial, this one uncontrolled, treated 35 stable RTRs with folic acid 10 mg/d for 3 months (50). In the 28 patients who completed the study, mean tHcy levels were reduced by approximately 25%, from 16.9 ± 6.4 to 12.8 ± 5.7 µmol/L (p < 0.0001).…”

Section: Treatment Of Hyperhomocysteinemiamentioning

confidence: 99%

“…They continue to have a very high prevalence of mild‐to‐moderate hyperhomocysteinemia despite the fortification of cereal grain products in the USA (10). Unlike ESRD dialysis‐dependent patients, they are to a large degree able to normalize their hyperhomocysteinemic state with supraphysiologic B‐vitamin therapy (49–52). They are a highly motivated population (54) who have frequent physician follow‐up, very often in large medical centers. Results in the RTRs can be extrapolated to the much larger CRI population (20).…”

Section: Rtrs As a Study Populationmentioning

confidence: 99%

“…Unlike ESRD dialysis‐dependent patients, they are to a large degree able to normalize their hyperhomocysteinemic state with supraphysiologic B‐vitamin therapy (49–52).…”

Section: Rtrs As a Study Populationmentioning

confidence: 99%

See 2 more Smart Citations

Hyperhomocysteinemia in Renal Transplant Recipients

Friedman

Rosenberg

Selhub

et al. 2002

American Journal of Transplantation

View full text Add to dashboard Cite

Renal transplantation is a commonly performed curative procedure for end-stage renal disease. With the increase in renal allograft half-lives, attention is now being focused on cardiovascular morbidity and death in the renal transplant recipient (RTR) population. Among the more novel cardiovascular disease (CVD) risk factors for which this group is at risk is hyperhomocysteinemia. Hyperhomocysteinemia has been associated with an increased risk of CVD, although prospective randomized trials designed to prove causality are still ongoing. Since plasma total homocysteine levels are inversely related to renal function, RTRs have a greatly increased prevalence of hyperhomocysteinemia. Other determinants of homocysteine include B-vitamins, albumin, age, and genetic polymorphisms. Although RTRs are resistant to the typical B-vitamin doses used to correct hyperhomocysteinemia in the general population, they do respond to supraphysiologic dose therapy. In terms of prevalence, etiology, and treatment of hyperhomocysteinemia, RTRs are very similar to the much larger chronic renal insufficiency population. For this reason, RTRs have been chosen as an ideal study population in investigating the effect of reducing hyperhomocysteinemia on CVD outcomes.

show abstract

Section: Treatment Of Hyperhomocysteinemiamentioning

confidence: 99%

Section: Rtrs As a Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Hyperhomocysteinemia in Renal Transplant Recipients

Friedman

Rosenberg

Selhub

et al. 2002

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…In one study, less than 2% of patients had homocysteine levels in the optimal range of less than 10 M (35). Homocysteine levels correlate inversely with renal function and folate levels in the majority of studies (32,33). Homocysteine levels increase with even mild renal impairment or folate deficiency, both of which are common in renal transplant recipients.…”

Section: Antiphospholipid Antibodiesmentioning

confidence: 96%

“…High homocysteine levels are found in 50% to 90% of renal transplant patients and in 30% of those with completely normal graft function (32)(33)(34). In one study, less than 2% of patients had homocysteine levels in the optimal range of less than 10 M (35).…”

Section: Antiphospholipid Antibodiesmentioning

confidence: 99%

Thrombophilia and Thrombotic Problems in Renal Transplant Patients

Kujovich¹

2004

Transplantation

View full text Add to dashboard Cite

Effect of Smoking on Development of New Onset Diabetes Mellitus after Transplantation (NODAT) of Kidney

Dedinská

Laca

Miklušica

et al. 2016

Acta Medica Martiniana

Self Cite

View full text Add to dashboard Cite

Purpose: Cigarette smoking has adverse effects on kidney transplant recipients, causing cardiovascular disease, kidney function impairment, and cancer. New onset diabetes mellitus after transplantation (NODAT) represents serious complication of transplantation of solid organs. Methods: In the group of 252 patients after kidney transplantation, we identified smokers and current non-smokers (the patient who has not been smoking or who is ex smoker) for the period of minimum 24 months. In the monitored period of 12 months after transplantation, we detected presence of NODAT in both groups. The group contained only those patients who did not have diabetes mellitus (of type 1 and 2) at the time of kidney transplantation. Results: The group of smokers was composed of 88 patients (34.9 %) and non-smokers 164 patients (65.1 %). The average age of smokers was 52 years ± 12.4, and of current non-smokers it was 44.8 years ± 12.8 (P < 0.0001). The smokers had significantly lower body mass index (BMI) at the time of kidney transplantation (P = 0.0059) and also 12 months after transplantation (P = 0.0069), lower weight gain 12 months after transplantation (P = 0.0220) and larger waist circumference 12 months after transplantation (P < 0.0001). Conclusion: In our group, smoking had no effect on development of NODAT, the smokers had lower values of BMI and waist circumference, however, the guideline development group feels that, as for the general population, success of smoking cessation can be enhanced by offering structured smoking cessation programs.

show abstract

Folic acid supplementation and homocyst(e)ine level in renal transplant recipients

Cited by 4 publications

References 6 publications

Hyperhomocysteinemia in Renal Transplant Recipients

Hyperhomocysteinemia in Renal Transplant Recipients

Thrombophilia and Thrombotic Problems in Renal Transplant Patients

Effect of Smoking on Development of New Onset Diabetes Mellitus after Transplantation (NODAT) of Kidney

Contact Info

Product

Resources

About